key: cord-0979953-l5isnile
authors: Saini, Kamal S.; Martins-Branco, Diogo; Tagliamento, Marco; Vidal, Laura; Singh, Navneet; Punie, Kevin; Saini, Monika Lamba; Chico, Isagani; Curigliano, Giuseppe; de Azambuja, Evandro; Lambertini, Matteo
title: Emerging issues related to COVID-19 vaccination in patients with cancer
date: 2021-06-16
journal: Oncol Ther
DOI: 10.1007/s40487-021-00157-1
sha: 8a152f3315a3c456c7751fad6c084bb8c24495fd
doc_id: 979953
cord_uid: l5isnile

Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.

Coronavirus disease 2019 (COVID-19) [1] , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in about 3.5 million deaths globally as of 26 May 2021, including about 721,000 in the European Union, 590,000 in the USA, and 128,000 in the UK.

The pandemic has had a severe impact on oncology care and research [2] [3] [4] [5] [6] [7] . While the majority of patients with COVID-19 remain pauci-or asymptomatic, about 10-15% have a more severe disease, with some developing a clinical syndrome that shares certain similarities with malignancy, including hyper-inflammation, immune dysfunction, and of most concern, widespread thrombosis [8] , with microangiopathy being of particular concern [9] .

Patients with underlying cancer who develop COVID-19 constitute a vulnerable population [10] . A meta-analysis of 33,879 patients with both COVID- 19 and cancer showed that their probability of death was 25.4% (95% CI 22.9-28.2) [11] . Patients with lung cancer and hematological malignancies are at highest risk, as are recipients of stem cell transplants and adoptive cellular therapies [12] [13] [14] . Effective measures should be taken to protect patients with cancer from contracting COVID-19, including prioritization of vaccination against SARS-CoV-2 [15] .

SARS-CoV-2 has a characteristic spike (S) protein which induces humoral and cellular immune responses against SARS-CoV-2, making it a potent target for vaccine development [16] .

According to the World Health Organization (WHO), there were 101 COVID-19 vaccines in clinical development and 184 vaccine candidates in preclinical development as of 26 May 2021. Most of them aim to elicit an immune response against the S protein [17] , and employ various COVID-19 vaccine platforms, such as nucleic acid, viral vector, protein subunit, inactivated or attenuated whole virus, and virus-like particle [16] .

As Several other COVID-19 vaccines have been approved by regulatory agencies of specific countries, including Sputnik V, Sinovac's Cor-onaVac, and AstraZeneca-University of Oxford-Serum Institute of India's Covishield [19] .

Most COVID-19 vaccine phase 3 studies have excluded the participation of patients with cancer. Hence, there are insufficient data regarding the safety or efficacy of these vaccines in this patient population. However, given the high mortality risk from SARS-CoV-2 infection among patients with cancer, the high efficacy of COVID-19 vaccines in preventing serious infection in the general population, and the low incidence of serious adverse effects, several professional oncology societies and other health organizations and agencies have advocated that the risk-benefit ratio is likely to be strongly in favor of vaccinating people with cancer [7, 20, 21] . A majority of patients with cancer, too, are supportive of getting vaccinated [22] . However, the global scenario is heterogeneous, with many low-income countries yet to prioritize vaccination of patients with cancer [23] .

Immune checkpoint inhibitors (ICIs) have been approved for the treatment of a wide variety of malignancies [24, 25] . There is a theoretical concern that COVID-19 vaccines that induce a primarily T H 1-type response, or contain vaccine adjuvants such as Matrix-M1 [26] , or toll-like receptor (TLR) 7/8 agonist molecule adsorbed to alum [27] , could have an impact on the toxicity or efficacy of ICIs. However, the safety data available so far are reassuring, with no evidence of increased immune-related adverse events. In a study from Israel, 134 patients with cancer with ongoing ICI therapy were administered two doses of the BNT162b2 vaccine [28] . The commonest local side effects were injection site pain (63%) and local swelling (9%), whereas the most frequent systemic side effects were muscle pain (34%), fatigue (34%), headache (16%), and fever, chills, and gastrointestinal complications (10% each). This toxicity profile was broadly similar between the cohort of ICI-treated patients with cancer and a matched cohort of healthy controls (HCs); no vaccine-related or ICI-related severe adverse events were observed.

In the UK SOAP-02 study, 95 patients with solid cancer, 56 patients with hematological cancer, and 54 healthy controls (HC) were enrolled [29] . Of these, 31 patients with cancer and 16 HCs were vaccinated with two doses of the BNT162b2 vaccine 21 days apart, while the others received only the prime dose of the vaccine at the time of reporting, and were scheduled to receive the boost dose 12 weeks later. In the overall cancer cohort, no toxicities were observed in 54% of the patients following the first dose, and in 71% of the patients following the second dose. In the HC cohort, no toxicities were reported in 38% after the first dose and in 31% after the second dose. Injection-site pain was the most common adverse event, and was recorded in 35% of the patients with cancer. No vaccine-related deaths were reported.

Rare events of venous or arterial thrombosis associated with thrombocytopenia (clinically resembling heparin-induced thrombocytopenia [HIT]) have been reported in people receiving AstraZeneca's ChAdOx1 nCoV-19 or Janssen's Ad. 26 .COV2.S [30, 31] . This syndrome has recently been termed by the US Centers for Disease Control and Prevention (CDC) as thrombosis with thrombocytopenia syndrome (TTS) [32] , and is also known as vaccine-induced immune thrombotic thrombocytopenia (VITT) [33] or vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) [34] . The thrombosis is often cerebral or abdominal in location and associated with platelet-activating antibodies against platelet factor 4 [33, 35] , and younger women seem to be at higher risk [36] . Per current guidance, administration of the anticoagulant heparin should be avoided in patients with potential TTS, unless testing for HIT is negative [37] . As of 12 May 2021, 23.9 million first doses and 9.0 million doses of the of the ChAdOx1 nCoV-19 have been administered in the UK, following which the Medicines and Healthcare products Regulatory Agency (MHRA) received 309 reports (169 in females, 138 in males, 2 of unknown gender) of major thromboembolic events with low platelets, including 116 cases (mean age 46 years) of cerebral venous sinus thrombosis with thrombocytopenia [38] . With 56 reported deaths among these 309 cases to date, the overall case fatality rate is 18%.

In a large population-based study from Denmark and Norway involving 281,264 people who received the ChAdOx1 nCoV-19 vaccine, 59 cases of venous thromboembolic events were observed among the vaccine recipients, compared with 30 expected based on the incidence rates in the general population, corresponding to a standardized morbidity ratio of 1.97 (1.50-2.54) [39] .

The MHRA has advised caution while using ChAdOx1 nCoV-19 in people of any age who are at higher risk of blood clots because of underlying medical conditions [40] . This guidance could impact patients with cancer, considering that malignancy itself is associated with an increased risk of thromboembolism [41] . Some countries have restricted the use of this vaccine to older age groups, even though the EMA and MHRA opine that based on data available on 26 May 2021, the benefits outweigh the risks in the majority of people.

According to the US FDA, 15 cases of thrombosis with thrombocytopenia have been reported up to 24 April 2021 among recipients of the Ad.26.COV2.S vaccine [42] . All of these cases occurred in women between the ages of 18 and 59 (median 37 years), with the onset of symptoms between 6 and 15 days after vaccination.

Thrombocytopenia following administration of mRNA vaccines BNT162b2 and mRNA-1273 has been reported in 20 patients (median age 41 years; 11 female) [43] . Of these, 17 had no pre-existing thrombocytopenia, while 14 reported bleeding symptoms prior to hospitalization.

Currently, there are limited data about the efficacy of COVID-19 vaccines in patients with cancer.

In the SOAP-02 study described above, measurement of anti-S protein immunoglobulin levels 21 days following the first dose of the BNT162b2 vaccine showed that 97% (31/32) of HCs, 39% (21/54) of patients with solid cancer, and only 13% (5/39) of patients with hematological cancer had developed an adequate level of immune protection. However, some of these serological non-responders demonstrated an increase in T cells secreting IFN-c and/or IL-2. Notably, among patients with solid cancers who received the boost dose at day 21, 95% (18/19) showed protective levels of anti-SARS-CoV-2 antibodies at week 5.

As a response to the current shortage of COVID-19 vaccine supply, some countries have adopted a policy of increasing the interval between vaccine doses. As an example, in the UK and British Columbia, Canada, the primeboost gap is currently 8 and 16 weeks, respectively. Emerging data show that increased gap improves the immunogenicity and efficacy of the ChAdOx1 nCoV-19 vaccine [44] . While this approach may be suitable for the general population with an intact immune system, results from the SOAP-02 and other studies raise the concern that a prolonged prime-boost interval may leave patients with cancer vulnerable to COVID-19 [45] .

While waiting for additional trial and realworld data to accrue, it may be prudent for policymakers to consider tailored time points for vaccinating patients with cancer or other causes of immunodeficiency.

Vulnerable patients with cancer could be further protected by vaccinating their caregivers and all care-home staff on priority.

Mutant variants of the wild-type (Wuhan) SARS-CoV-2 virus have been documented in most geographies of the world, and are tracked by online databases such as https://www.gisaid.org/ hcov19-variants/. Knowledge regarding these variants is rapidly evolving. Currently, the variants of concern include B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta), which were first identified in the UK, South Africa, Brazil, and India, respectively. Such viral variants may differ with respect to transmissibility, lethality, and response to vaccines [46] .

In a study of 2026 adults in South Africa, the ChAdOx1 nCoV-19 vaccine did not confer any significant protection against mild-to-moderate COVID-19 due to the B.1.351 variant [47] . A post hoc analysis found that efficacy against symptomatic COVID-19 of ChAdOx1 nCoV-19 was 70.4% for the B.1.1.7 variant and 81.5% for non-B.1.1.7 variants [48] .

A population-scale study from Qatar showed that the effectiveness of the BNT162b2 vaccine was 89.5% (95% CI, 85.9-92.3) against the B.1.1.7 variant and 75.0% (95% CI, 70.5-78.9) against the B.1.351 variant [49] .

There is rising concern that patients with an immunocompromised state, such as those with cancer, could develop long-lasting or persistent SARS-CoV-2 infection, which could accelerate viral evolution and emergence of variants [50] . Patients with cancer have been shown to carry significantly higher intra-host viral genetic diversity than their non-cancer counterparts [51] The clinical impact of SARS-CoV-2 variants on patients with cancer is currently unknown. [52, 53] , and such heterologous prime-boost combinations could be approved for use in the future. • Even though COVID-19 vaccines currently have an emergency use authorization rather than full authorization, the US FDA has clarified that patients on clinical trials may receive COVID-19 vaccines, and this will not be considered a protocol deviation in studies that disallow the concurrent use of investigational agents [54] . • Optimal timing of the vaccination vis-à-vis the administration of anti-cancer therapy is an important clinical consideration; vaccines should ideally be administered at a time when the patient's immune system is least perturbed by therapy; operational guidance is emerging [55, 56] . • Transient axillary lymphadenopathy has been reported following COVID-19 vaccination. The Society of Breast Imaging has recommended that if feasible, women should consider scheduling their screening mammograms prior to the first dose or 4-6 weeks following the second dose of a COVID-19 vaccination [57] . Additionally, for patients with breast cancer, consider administering the vaccine in the thigh or the contralateral arm [58] . • The US CDC had previously suggested that any other vaccine should be given at least 14 days before or after the COVID-19 vaccine, partly to avoid incorrect attribution of potential adverse events. This guidance has been recently updated, and COVID-19 vaccines and other vaccines (including the influenza vaccine) may now be administered without regard to timing. The CDC advises that in the case of co-administration of multiple vaccines, the COVID-19 vaccines and vaccines such as tetanus toxoid-containing and adjuvanted vaccines that may be more likely to cause a local reaction should preferably be administered in different limbs [59] . • Live attenuated viral vaccines are generally avoided in patients with cancer; this should apply to future COVID-19 vaccines based on this technology platform as well.

Currently, most COVID-19 vaccines employ a two-dose schedule, a notable exception being Ad.26.COV2.S. which is given as a single dose. Some patients with cancer may have incomplete immune reconstitution following anticancer therapy, or may have an immunocompromised status as a result of their disease, and hence they may generate a suboptimal protective response following a two-dose schedule. Three-dose schedules of COVID-19 vaccines are currently in clinical trials (e.g., NCT04368728) in healthy volunteers, and similar trials are needed for patients with cancer as well.

The VOICE study (ClinicalTrials.gov identifier, NCT04715438, target sample size 873) aims to recruit patients with cancer being treated with chemotherapy, immunotherapy, or combination chemo-immunotherapy, and HCs, in order to assess side effects and the kinetics and strength of immune responses to COVID-19 vaccination. Results from this and similar studies from other countries will be valuable in designing future vaccination strategies for patients with cancer.

Several registries have been set up for collecting real-world COVID-19 data related to patients with cancer, and are generating valuable data and contributing to the scientific understanding of the ongoing pandemic [60] .

Future late-phase COVID-19 vaccine trials should allow an adequate number of patients with cancer to participate as well [7] .

Funding. No funding or sponsorship was received for this study or publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Compliance with ethics guidelines. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Consent to publish. All authors have reviewed the final version of this manuscript and provided their consent to publish.

Data availability. All data and references mentioned in this manuscript are from publicly available sources. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/.

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Effect of the COVID-19 pandemic on cancer treatment and research

Reimagining global oncology clinical trials for the postpandemic era: a call to arms

Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists. ESMO Open

Cancer care during the spread of coronavirus disease (COVID-19) in Italy: young oncologists' perspective. ESMO Open

Cancer treatment and research during the COVID-19 pandemic: experience of the first 6 months

SARS-CoV-2 vaccines for cancer patients: a call to action

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis

Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis

Challenges of cellular therapy during the COVID-19 pandemic

A rationale to prioritise vaccination of HSCT patients against COVID-19

Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Draft landscape and tracker of COVID-19 candidate vaccines

Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers -eight U.S. Locations, Oncol Ther

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: vaccinate monitor educate

COVID-19 vaccines for patients with cancer: benefits likely outweigh risks

Attitudes of patients with cancer towards vaccinations-results of online survey with special focus on the vaccination against COVID-19

Cancer and COVID-19 vaccines: a complex global picture

Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics

Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

Adjuvantation helps to optimise COVID-19 vaccine candidate

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26COV2S vaccination

Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC subcommittee on platelet immunology

Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia)

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet Lond Engl

CDC Health Alert Network (2021) Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson and Johnson COVID-19 Vaccine

Coronavirus vaccine -weekly summary of yellow card reporting

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Press Release: MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots

Supportive care in patients with cancer during the COVID-19 pandemic

US Food and Drug Administration. FDA News Release (2021) FDA and CDC lift recommended pause on Johnson and Johnson (Janssen) COVID-19 vaccine use following thorough safety review

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Interplay between emerging SARS-CoV-2 variants and pandemic control

Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B117 and B1351 Variants

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. The Lancet

Mix-and-match COVID vaccines trigger potent immune response

Food and Drug Administration (2021) Conduct of clinical trials of medical products during the COVID-19 public health emergency. guidance for industry, investigators, and institutional review boards

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

COVID-19 vaccines in patients with cancer-a welcome addition, but there is need for optimization

COVID-19 vaccinationrelated lymphadenopathy: what to be aware

Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: a pragmatic approach

Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States

COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic